Back to Journals » ClinicoEconomics and Outcomes Research » Volume 7
![](https://www.dovepress.com/cr_data/cache/journal_image/29/cope/thumb_100_1000_100.jpg)
ClinicoEconomics and Outcomes Research
ISSN: 1178-6981
- View all (876)
- Volume 16, 2024 (29)
- Volume 15, 2023 (67)
- Volume 14, 2022 (61)
- Volume 13, 2021 (90)
- Volume 12, 2020 (70)
- Volume 11, 2019 (71)
- Volume 10, 2018 (77)
- Volume 9, 2017 (77)
- Volume 8, 2016 (73)
- Volume 7, 2015 (64)
- Volume 6, 2014 (53)
- Volume 5, 2013 (59)
- Volume 4, 2012 (41)
- Volume 3, 2011 (19)
- Volume 2, 2010 (16)
- Volume 1, 2009 (9)
Archive: Volume 7, 2015
![Video](assets/img/article_icons/video.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir
![](assets/img/youtube_social_icon_dark.png)
![](http://img.youtube.com/vi/dJ4Xv4DZkMU/1.jpg)
Walker DR, Juday TR, Manthena SR, Jing Y, Sood V
ClinicoEconomics and Outcomes Research 2015, 7:637-642
Published Date: 17 December 2015
![Noteworthy comment: Foreign utilities of the EQ-5D-3L are not readily transferrable to economic evaluations conducted from a national perspective. The present study aimed to develop a method for adjusting mean utilities to make them transferable from one country to another. The present study showed that it is feasible to develop and validate regression models for adjusting mean utility estimates valued by foreign value sets that are systematically different than the national value set. The paper showed that adjustment has the potential to increase the transferability of a foreign utility to a national setting.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Adjustment of foreign EQ-5D-3L utilities can increase their transferability
Oddershede L, Petersen KD
ClinicoEconomics and Outcomes Research 2015, 7:629-636
Published Date: 15 December 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Estimating health-state utility values for patients with recurrent ovarian cancer using Functional Assessment of Cancer Therapy – General mapping algorithms
Hettle R, Borrill J, Suri G, Wulff J
ClinicoEconomics and Outcomes Research 2015, 7:615-627
Published Date: 26 November 2015
![Noteworthy comment: Pre-existing gastrointestinal events may deter the use of pharmacological treatment in patients diagnosed with osteoporosis. This study examine the association between pre-existing gastrointestinal events and osteoporosis, pharmacotherapy initiation among women diagnosed with osteoporosis, through claims data from a large US managed care database.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Gastrointestinal events and association with initiation of treatment for osteoporosis
Modi A, Siris ES, Tang J, Sajjan S, Sen SS
ClinicoEconomics and Outcomes Research 2015, 7:603-613
Published Date: 25 November 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Productivity loss and resource utilization, and associated indirect and direct costs in individuals providing care for adults with schizophrenia in the EU5
Gupta S, Isherwood G, Jones K, Van Impe K
ClinicoEconomics and Outcomes Research 2015, 7:593-602
Published Date: 25 November 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Relative cost-effectiveness of using an extensively hydrolyzed casein formula containing the probiotic Lactobacillus rhamnosus GG in managing infants with cow’s milk allergy in Spain
Guest JF, Weidlich D, Mascuñán Díaz JI, Díaz JJ, Ojeda PM, Ferrer-González JP, Gil D, Onrubia I, Rincón Víctor P
ClinicoEconomics and Outcomes Research 2015, 7:583-591
Published Date: 23 November 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Doctors commitment and long-term effectiveness for cost containment policies: lesson learned from biosimilar drugs
Menditto E, Orlando V, Coretti S, Putignano D, Fiorentino D, Ruggeri M
ClinicoEconomics and Outcomes Research 2015, 7:575-581
Published Date: 11 November 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Variation in hospital resource use and cost among surgical procedures using topical absorbable hemostats
Martyn D, Meckley LM, Miyasato G, Lim S, Riebman JB, Kocharian R, Scaife JG, Rao Y, Corral M
ClinicoEconomics and Outcomes Research 2015, 7:567-574
Published Date: 6 November 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Impact of treatment with rosuvastatin and atorvastatin on cardiovascular outcomes: evidence from the Archimedes-simulated clinical trials
Colivicchi F, Sternhufvud C, Gandhi SK
ClinicoEconomics and Outcomes Research 2015, 7:555-565
Published Date: 27 November 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The financial burden of sickle cell disease on households in Ekiti, Southwest Nigeria
Olatunya OS, Ogundare EO, Fadare JO, Oluwayemi IO, Agaja OT, Adeyefa BS, Aderiye O
ClinicoEconomics and Outcomes Research 2015, 7:545-553
Published Date: 4 November 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The expenditures related to the use of antifungal drugs in patients with hematological cancers: a cost analysis
Gedik H
ClinicoEconomics and Outcomes Research 2015, 7:537-543
Published Date: 3 November 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Cost-effectiveness of three echinocandins and fluconazole in the treatment of candidemia and/or invasive candidiasis in nonneutropenic adult patients
Grau S, Pozo JC, Romá E, Salavert M, Barrueta JA, Peral C, Rodriguez I, Rubio-Rodríguez D, Rubio-Terrés C
ClinicoEconomics and Outcomes Research 2015, 7:527-535
Published Date: 13 October 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Linezolid for the treatment of hospital-acquired pneumonia in a Chinese tertiary hospital
Lesher BA, Liu Z, Chen Y, Gao X
ClinicoEconomics and Outcomes Research 2015, 7:521-526
Published Date: 9 October 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Cost-effectiveness analysis of pregabalin for treatment of chronic low back pain in patients with accompanying lower limb pain (neuropathic component) in Japan
Igarashi A, Akazawa M, Murata T, Taguchi T, Sadosky A, Ebata N, Willke R, Fujii K, Doherty J, Kobayashi M
ClinicoEconomics and Outcomes Research 2015, 7:505-520
Published Date: 7 October 2015
![Noteworthy comment: Most economic evaluation models compare a new patented drug (NPRx) to a generic comparator. The objective of this study was to examine the impact on the ICER of the future introduction of lower cost generic versions of the a new patented drug (NPRx) within the model’s time horizon. ICER estimated within economic evaluations comparing NPRx to generic comparators which ignore the future introduction of lower cost generic versions of the NPRx within the model’s time horizon will tend to be overestimated. Inclusion of this parameter should be considered within future economic evaluations.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Bias within economic evaluations – the impact of considering the future entry of lower-cost generics on currently estimated incremental cost-effectiveness ratios of a new drug
Guertin JR, Mitchell D, Ali F, LeLorier J
ClinicoEconomics and Outcomes Research 2015, 7:497-503
Published Date: 6 October 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Annual impact of scribes on physician productivity and revenue in a cardiology clinic
Bank AJ, Gage RM
ClinicoEconomics and Outcomes Research 2015, 7:489-495
Published Date: 30 September 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Estimating the health care burden of prescription opioid abuse in five European countries
Shei A, Hirst M, Kirson NY, Enloe CJ, Birnbaum HG, Dunlop WCN
ClinicoEconomics and Outcomes Research 2015, 7:477-488
Published Date: 15 September 2015
![Noteworthy comment: In health technology assessment (HTA) agencies where cost-effectiveness plays a role in decision-making, an incremental cost-effectiveness ratio (ICER) threshold is often used to inform reimbursement decisions. Acceptance of submissions with higher-than-threshold ICERs varied by HTA agency and was not significantly influenced by disease category. Such submissions must be accompanied by robust, concrete, and transparent evidence in order to achieve patient access.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Acceptance of health technology assessment submissions with incremental cost-effectiveness ratios above the cost-effectiveness threshold
Griffiths EA, Hendrich JK, Stoddart SDR, Walsh SCM
ClinicoEconomics and Outcomes Research 2015, 7:463-476
Published Date: 31 August 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Review of the cost of venous thromboembolism
Fernandez MM, Hogue S, Preblick R, Kwong WJ
ClinicoEconomics and Outcomes Research 2015, 7:451-462
Published Date: 28 August 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
AbobotulinumtoxinA in the management of cervical dystonia in the United Kingdom: a budget impact analysis
Abogunrin S, Brand S, Desai K, Dinet J, Gabriel S, Harrower T
ClinicoEconomics and Outcomes Research 2015, 7:441-449
Published Date: 9 September 2015
![Noteworthy comment: The aim of this article was to investigate the economic outcomes and relevance of HAART for people living with HIV. In general, HAART is more cost-effective than other therapeutic regimens available to date. As combination antiretroviral regimens have become more potent and popular in both developed countries and developing countries, it is important to administer HAART at the appropriate time and among appropriate people.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
A narrative review of cost-effectiveness analysis of people living with HIV treated with HAART: from interventions to outcomes
Tse WF, Yang W, Huang W
ClinicoEconomics and Outcomes Research 2015, 7:431-439
Published Date: 11 August 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study
North RT, Harvey VJ, Cox LC, Ryan SN
ClinicoEconomics and Outcomes Research 2015, 7:423-430
Published Date: 29 July 2015
![Noteworthy comment: This study was conducted to estimate the clinical and economic impact that remains associated with uncontrolled surgical bleeding, even when hemostats are used during surgery. Uncontrolled intraoperative bleeding despite hemostat use is prevalent and associated with significantly higher hospital costs and worse clinical outcomes across several surgical procedures compared to controlled bleeding. There is an unmet need for newer hemostats that can more effectively control bleeding, improve outcomes, and reduce hospital resource use.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Health and economic outcomes associated with uncontrolled surgical bleeding: a retrospective analysis of the Premier Perspectives Database
Corral M, Ferko N, Hollmann S, Broder MS, Chang E
ClinicoEconomics and Outcomes Research 2015, 7:409-421
Published Date: 22 July 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Retrospective analysis of drug utilization, health care resource use, and costs associated with IFN therapy for adjuvant treatment of malignant melanoma
Zhang Y, Le TK, Shaw JW, Kotapati S
ClinicoEconomics and Outcomes Research 2015, 7:397-407
Published Date: 21 July 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Relationship between patient dependence and direct medical-, social-, indirect-, and informal-care costs in Spain
Darbà J, Kaskens L
ClinicoEconomics and Outcomes Research 2015, 7:387-395
Published Date: 2 July 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Impact of noncommunicable diseases in the State of Qatar
Al-Kaabi SK, Atherton A
ClinicoEconomics and Outcomes Research 2015, 7:377-385
Published Date: 2 July 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Cost and effectiveness of omega-3 fatty acid supplementation in Chinese ICU patients receiving parenteral nutrition
Wu GH, Gao J, Ji CY, Pradelli L, Xi QL, Zhuang QL
ClinicoEconomics and Outcomes Research 2015, 7:369-375
Published Date: 26 June 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Association of persistent and transient worsening renal function with mortality risk, readmissions risk, length of stay, and costs in patients hospitalized with acute heart failure
Palmer JB, Friedman HS, Waltman Johnson K, Navaratnam P, Gottlieb SS
ClinicoEconomics and Outcomes Research 2015, 7:357-367
Published Date: 19 June 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Economic value of in vitro fertilization in Ukraine, Belarus, and Kazakhstan
Mandrik O, Knies S, Severens JL
ClinicoEconomics and Outcomes Research 2015, 7:347-356
Published Date: 12 June 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Medical costs associated with cardiovascular events among high-risk patients with hyperlipidemia
Bonafede MM, Johnson BH, Richhariya A, Gandra SR
ClinicoEconomics and Outcomes Research 2015, 7:337-345
Published Date: 9 June 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Relative cost-effectiveness of an extensively hydrolyzed casein formula containing the probiotic Lactobacillus rhamnosus GG in managing infants with cow's milk allergy in Italy
Guest JF, Panca M, Ovcinnikova O, Nocerino R
ClinicoEconomics and Outcomes Research 2015, 7:325-336
Published Date: 8 June 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease
Schuetz CA, Ong SH, Blüher M
ClinicoEconomics and Outcomes Research 2015, 7:313-323
Published Date: 5 June 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Comparative effectiveness and costs of generic and brand-name gabapentin and venlafaxine in patients with neuropathic pain or generalized anxiety disorder in Spain
Sicras-Mainar A, Rejas-Gutiérrez J, Navarro-Artieda R
ClinicoEconomics and Outcomes Research 2015, 7:299-312
Published Date: 4 June 2015
![Noteworthy comment: The results of this research led to recommendations for improvement and the potential extrapolation of these best practices to other HTA organizations worldwide, along with suggestions for pan-Canadian Oncology Drug Review (pCODR’s) continued evolution in conjunction with its integration into Canadian Agency for Drugs and Technologies in Health (CADTH). It is clear that the transition of pCODR to CADTH provides an opportunity for these newly-amalgamated HTA agencies in Canada](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Evolution of health technology assessment: best practices of the pan-Canadian Oncology Drug Review
Rocchi A, Chabot I, Glennie J
ClinicoEconomics and Outcomes Research 2015, 7:287-298
Published Date: 3 June 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Prevalence and cost of imaging in inpatient falls: the rising cost of falling
Fields J, Alturkistani T, Kumar N, Kanuri A, Salem DN, Munn S, Blazey-Martin D
ClinicoEconomics and Outcomes Research 2015, 7:281-286
Published Date: 3 June 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Adherence to statin treatment following a myocardial infarction: an Italian population-based survey
Monaldi B, Bologna G, Costa GG, D'Agostino C, Ferrante F, Filice M, Grion A, Mingarelli A, Paloscia L, Tettamanti R, Veronesi C, Degli Esposti L
ClinicoEconomics and Outcomes Research 2015, 7:273-280
Published Date: 1 June 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan
Mahlich J, Nishi M, Saito Y
ClinicoEconomics and Outcomes Research 2015, 7:267-272
Published Date: 22 May 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Application of a validated algorithm to estimate the effectiveness and cost of biologics for rheumatoid arthritis in the US pharmacy benefit manager context
Wu N, Bhurke S, Shah N, Harrison DJ
ClinicoEconomics and Outcomes Research 2015, 7:257-266
Published Date: 13 May 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective
Dranitsaris G, Yu B, King J, Kaura S, Zhang A
ClinicoEconomics and Outcomes Research 2015, 7:249-256
Published Date: 12 May 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective
Régnier SA, Malcolm W, Haig J, Xue W
ClinicoEconomics and Outcomes Research 2015, 7:235-247
Published Date: 6 May 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
A potential gender bias in assessing quality of life – a standard gamble experiment among university students
Al Obaidi L, Mahlich J
ClinicoEconomics and Outcomes Research 2015, 7:227-233
Published Date: 24 April 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Incorporating ulipristal acetate in the care of symptomatic uterine fibroids: a Canadian cost-utility analysis of pharmacotherapy management
Tsoi B, Blackhouse G, Ferrazzi S, Reade CJ, Chen I, Goeree R
ClinicoEconomics and Outcomes Research 2015, 7:213-225
Published Date: 17 April 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Inpatient cost of treating osteoporotic fractures in mainland China: a descriptive analysis
Yang YC, Du F, Ye WY, Chen Y, Li JH, Zhang J, Nicely H, Burge R
ClinicoEconomics and Outcomes Research 2015, 7:205-212
Published Date: 13 April 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Health economic evaluations of medical devices in the People's Republic of China: A systematic literature review
Zhang R, Modaresi F, Borisenko O
ClinicoEconomics and Outcomes Research 2015, 7:195-204
Published Date: 9 April 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Budget impact analysis of botulinum toxin A therapy for upper limb spasticity in the United Kingdom
Abogunrin S, Hortobagyi L, Remak E, Dinet J, Gabriel S, Bakheit AM
ClinicoEconomics and Outcomes Research 2015, 7:185-193
Published Date: 1 April 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The impact of chronic pain on direct medical utilization and costs in chronic obstructive pulmonary disease
Roberts MH, Mapel DW, Thomson HN
ClinicoEconomics and Outcomes Research 2015, 7:173-184
Published Date: 26 March 2015
![Noteworthy comment: Disability Adjusted Life Years (DALYs) lost to diabetes as the sum of years of life lost and years lived with disability were estimated by gender and age using country-specific epidemiological data and global disability weights. In spite of data limitations, the estimates reported here show that DALY loss due to diabetes imposes a substantial burden on countries. Cross-national variation in disease epidemiology was the largest source of variation in the burden of diabetes between countries.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Disability-adjusted life years lost due to diabetes in France, Italy, Germany, Spain, and the United Kingdom: a burden of illness study
Darbà J, Kaskens L, Detournay B, Kern W, Nicolucci A, Orozco-Beltrán D, Ramírez de Arellano A
ClinicoEconomics and Outcomes Research 2015, 7:163-171
Published Date: 23 March 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece [Corrigendum]
Fragoulakis V, Raptis E, Vitsou E, Maniadakis N
ClinicoEconomics and Outcomes Research 2015, 7:161-162
Published Date: 17 March 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Costs of illness analysis in Italian patients with chronic obstructive pulmonary disease (COPD): an update
Dal Negro RW, Bonadiman L, Turco P, Tognella S, Iannazzo S
ClinicoEconomics and Outcomes Research 2015, 7:153-159
Published Date: 16 March 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Cost-effectiveness of using an extensively hydrolyzed casein formula plus the probiotic Lactobacillus rhamnosus GG compared to an extensively hydrolyzed formula alone or an amino acid formula as first-line dietary management for cow’s milk allergy in the US
Ovcinnikova O, Panca M, Guest JF
ClinicoEconomics and Outcomes Research 2015, 7:145-152
Published Date: 27 February 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Health services financing and delivery: analysis of policy options for Dubai, United Arab Emirates
Hamidi S
ClinicoEconomics and Outcomes Research 2015, 7:133-143
Published Date: 25 February 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data
Knight T, Schaefer C, Krasa H, Oberdhan D, Chapman A, Perrone RD
ClinicoEconomics and Outcomes Research 2015, 7:123-132
Published Date: 20 February 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Health economics, equity, and efficiency: are we almost there?
Ferraz MB
ClinicoEconomics and Outcomes Research 2015, 7:119-122
Published Date: 12 February 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain
Darbà J, Kaskens L, Sorio Vilela F, Lothgren M
ClinicoEconomics and Outcomes Research 2015, 7:105-117
Published Date: 9 February 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies
McDonell AL, Kiiskinen U, Zammit DC, Kotchie RW, Thuresson PO, Nicolay C, Haslam T, Bruinsma M, Janszen-Van Oosterhout AJ, Otto T
ClinicoEconomics and Outcomes Research 2015, 7:95-103
Published Date: 30 January 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Economic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece
Fragoulakis V, Vitsou E, Hernandez AC, Maniadakis N
ClinicoEconomics and Outcomes Research 2015, 7:85-93
Published Date: 16 January 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece
Fragoulakis V, Raptis E, Vitsou E, Maniadakis N
ClinicoEconomics and Outcomes Research 2015, 7:73-83
Published Date: 8 January 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
End-stage renal disease in autosomal dominant polycystic kidney disease: a comparison of dialysis-related utilization and costs with other chronic kidney diseases
Brunelli SM, Blanchette CM, Claxton AJ, Roy D, Rossetti S, Gutierrez B
ClinicoEconomics and Outcomes Research 2015, 7:65-72
Published Date: 6 January 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Value analysis of digital breast tomosynthesis for breast cancer screening in a commercially-insured US population
Bonafede MM, Kalra VB, Miller JD, Fajardo LL
ClinicoEconomics and Outcomes Research 2015, 7:53-63
Published Date: 12 January 2015
![Noteworthy comment: This study aimed to build a predictive model of unplanned readmissions within 30 days of an initial COPD-caused hospitalization. Reducing avoidable hospital readmissions is a quality improvement and cost containment strategy that receives much attention from both public and private payers in all countries.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Assessing the importance of predictors in unplanned hospital readmissions for chronic obstructive pulmonary disease
Yu TC, Zhou H, Suh K, Arcona S
ClinicoEconomics and Outcomes Research 2015, 7:37-51
Published Date: 6 January 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Cost of HAART in Italy: multicentric evaluation and determinants from a large HIV outpatient cohort
Tontodonati M, Cenderello G, Celesia BM, Trezzi M, Ursini T, Costantini A, Marra D, Polilli E, Catalani C, Butini L, Sozio F, Mazzotta E, Sciacca A, Rizzardini G, Manzoli L, Cozzi-Lepri A, Parruti G
ClinicoEconomics and Outcomes Research 2015, 7:27-35
Published Date: 22 December 2014
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Cost–consequence analysis of long-term prophylaxis in the treatment of von Willebrand disease in the Italian context
Schinco P, Cultrera D, Valeri F, Borchiellini A, Mantuano M, Gorla F, Savarese A, Teruzzi C
ClinicoEconomics and Outcomes Research 2015, 7:17-25
Published Date: 17 December 2014
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review
Chouaïd C, Crequit P, Borget I, Vergnenegre A
ClinicoEconomics and Outcomes Research 2015, 7:9-15
Published Date: 15 December 2014
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The costs of fluid overload in the adult intensive care unit: is a small-volume infusion model a proactive solution?
Child DL, Cao Z, Seiberlich LE, Brown H, Greenberg J, Swanson A, Sewall MR, Robinson SB
ClinicoEconomics and Outcomes Research 2015, 7:1-8
Published Date: 15 December 2014